Uterine Cervix CancerФаза 2NCT06331468
Hypofractionated Radiochemotherapy
Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
40 Phase 2 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Ovary and gynecologic40 studies
Uterine Cervix CancerФаза 2NCT06331468
Cisplatin, intensity modulated radiation therapy (IMRT), high-dose-rate (HDR) brachytherapy
Uterine LeiomyosarcomaФаза 2NCT05649956
Letrozole
Cervical CancerФаза 2NCT05838521
Sacituzumab govitecan
Ovarian CancerФаза 2NCT04918186Papers
Durvalumab, BA3011, BA3021, ENB003
Recurrent Endometrial CarcinomaФаза 2NCT04469764
Abemaciclib, Anastrozole, Letrozole
Ovarian CancerФаза 2NCT06906341
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Ovarian CancerФаза 2NCT04606914
mirvetuximab soravtansine (MIRV; IMGN853)
Ovary CancerФаза 2NCT05887609
Mirvetuximab Soravtansine-gynx, Olaparib
Platinum-resistant Ovarian CancerФаза 2NCT06710288
Gemcitabine, N-803, M-CENK
Ovarian CancerФаза 2NCT05952453
Carboplatin, olaparibp, embro
Endometrial CancerФаза 2NCT03832361
IMGN853
Ovarian NeoplasmsФаза 2NCT04641247
Niraparib
HER2/Neu+ Uterine Serous CarcinomaФаза 2NCT02491099Papers
Afatinib
Platinum-Resistant Fallopian Tube CarcinomaФаза 2NCT05538091
Vismodegib, Atezolizumab
Ovarian CancerФаза 2NCT05071937
ZEN003694, Talazoparib
Cervical CancersФаза 2NCT07022470
3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy